Nursing and Health Professions
Pioglitazone
100%
Diabetes Mellitus
50%
Patient with Type 2 Diabetes
50%
Metabolic Parameters
50%
Inflammation
33%
Follow up
33%
Combination Therapy
33%
C Reactive Protein
33%
Inpatient
33%
Control
33%
Heart Rate Variability
33%
Anthropometric Parameters
33%
Blood Level
16%
Cardiovascular Disease
16%
Standard
16%
Open-Label Trial
16%
Electrocardiogram
16%
Laboratory
16%
Holter Monitoring
16%
Medicine and Dentistry
Pioglitazone
100%
Patient
100%
Autonomic Function
66%
Diabetes Mellitus
50%
Follow up
33%
Combination Therapy
33%
Metabolic Regulation
33%
Serositis
33%
C Reactive Protein
33%
Heart Rate Variability
33%
Age
16%
Cardiovascular Disease
16%
Electrocardiogram
16%
Holter Monitoring
16%
Short Course Therapy
16%
Antiinflammatory Activity
16%
Open-Label Trial
16%
Neuroscience
Pioglitazone
100%
Heart Rate Variability
33%
C-Reactive Protein
33%
Diabetes
16%
Anti-Inflammatory
16%
Open-Label Trial
16%
Pharmacology, Toxicology and Pharmaceutical Science
Pioglitazone
100%
Diabetes Mellitus
50%
C Reactive Protein
33%
Open-Label Trial
16%